21 May 2013
Keywords: benefix, rights, revert, wyeth, after, end, baxter
Article | 09 July 2007
US drug major Wyeth has assumed all marketing and distribution rights to BeneFIX Coagulation Factor IX (recombinant) in Europe, following ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 2007
20 May 2013
© 2013 thepharmaletter.com